| 唑来膦酸对骨质转移的神经母细胞瘤儿童生存的影响 |
| |
| 引用本文： | 谈 珍,何珂骏,汤梦婕,张 勤,袁晓军,吴晔明. 唑来膦酸对骨质转移的神经母细胞瘤儿童生存的影响[J]. 同济大学学报(医学版), 2019, 40(2): 196-200 |
| |
| 作者姓名： | 谈 珍 何珂骏 汤梦婕 张 勤 袁晓军 吴晔明 |
| |
| 作者单位： | 上海交通大学医学院附属新华医院儿童血液肿瘤科，上海 200092,上海交通大学医学院附属新华医院儿童血液肿瘤科，上海 200092,上海交通大学医学院附属新华医院儿童血液肿瘤科，上海 200092,上海交通大学医学院附属新华医院儿童血液肿瘤科，上海 200092,上海交通大学医学院附属新华医院儿童血液肿瘤科，上海 200092,上海交通大学医学院附属新华医院儿外科 200092 |
| |
| 基金项目： | 国家自然科学基金面上项目（81572918）；上海卫健委课题（ZY(2018-2020)-FWTX-3012） |
| |
| 摘 要： | 目的 回顾分析应用唑来膦酸对于骨质转移的高危组神经母细胞瘤患儿5年生存率的影响。方法 回顾性分析2012年1月至2015年12月初诊并治疗的骨质转移的高危组神经母细胞瘤儿童36例，其中13例儿童使用唑来膦酸，剂量2.3mg/m2，在化疗前1d静脉滴注。结果 36例骨质转移神经母细胞瘤患者的5年无病生存率为13.3%，总体生存率为32.5%，患者生存时间最少8个月，最大随访时间72个月，中位生存时间41.4个月。使用唑来膦酸的13例骨质转移神经母细胞瘤患儿与同期常规化疗的23例患儿比较，总体生存率有显著提高(65.9% vs 13%，P=0.001)。结论 对于骨质转移的高危组神经母细胞瘤儿童，常规化疗中加用唑来膦酸可能延长总体生存率，经济有效，值得进一步开展前瞻性研究。
|
| 关 键 词： | 神经母细胞瘤； 高危组； 骨质转移； 唑来膦酸 |
| 收稿时间： | 2018-12-01 |
Effect of zoledronic acid on survival of children with bone metastatic neuroblastoma |
| |
| TAN Zhen,HE Ke-jun,TANG Meng-jie,ZHANG Qin,YUAN Xiao-jun and WU Ye-ming. Effect of zoledronic acid on survival of children with bone metastatic neuroblastoma[J]. Journal of Tongji University(Medical Science), 2019, 40(2): 196-200 |
| |
| Authors: | TAN Zhen HE Ke-jun TANG Meng-jie ZHANG Qin YUAN Xiao-jun WU Ye-ming |
| |
| Affiliation: | Dept. of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China,Dept. of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China,Dept. of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China,Dept. of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China,Dept. of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China and Dept. of Pediatric Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China |
| |
| Abstract: | Objective To investigate the effect of zoledronic acid (ZA) on the survival of children with bone metastatic neuroblastoma. Methods Clinical data of 36 patients with bone metastatic neuroblastoma admitted between January 2012 and December 2015 were retrospectively analyzed. All patients received chemotherapy, additional Zoledronic acid (2.3 mg/m2) was given to 13 patients (ZA group). Results The 5-year event free survival (EFS) and overall survival (OS) of 36 patients were 13.3% and 32.5% respectively. The patient survived at least 8 months and the maximum follow up was 72 months (median 41.4 months). Compared to patients treated with conventional chemotherapy alone, the 5-year overall survival in ZA group was improved significantly (65.9% vs 13%, P=0.001). Conclusion Zoledronic acid combined with conventional chemotherapy may improve the survival of neuroblastoma pediatric patients with bone metastasis, indicating that further prospective studies are necessary. |
| |
| Keywords: | neuroblastoma high risk bone metastasis zoledronic acid |
|
| 点击此处可从《同济大学学报(医学版)》浏览原始摘要信息 |
|
点击此处可从《同济大学学报(医学版)》下载全文 |
|
